UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials

Cancer chemotherapy and pharmacology, 2021-11, Vol.88 (5), p.899-910

2021

Volltextzugriff (PDF)

Magnetic bead extraction with acid dissociation immunoassay for the determination of serum CD80-Fc fusion protein

Bioanalysis, 2021-01, Vol.13 (2), p.89-100

2021

Volltextzugriff (PDF)

Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation

The AAPS journal, 2013-07, Vol.15 (3), p.646-658

2013

Volltextzugriff (PDF)

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

mAbs, 2021-01, Vol.13 (1), p.1981202-1981202

2021

Volltextzugriff (PDF)

Application and interpretation of free and total drug measurements in the development of biologics

Bioanalysis, 2011-06, Vol.3 (11), p.1287-1295

Ahene, Ago B

2011

Volltextzugriff (PDF)

Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats

Toxins, 2019-06, Vol.11 (6), p.345

2019

Volltextzugriff (PDF)

Ligand Binding Assays in the 21st Century Laboratory—A Call for Change

The AAPS journal, 2012-09, Vol.14 (3), p.377-379

2012

Volltextzugriff (PDF)

Ligand Binding Assays in the 21st Century Laboratory: Automation

The AAPS journal, 2012-03, Vol.14 (1), p.142-153

2012

Volltextzugriff (PDF)

Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development

The AAPS journal, 2011-03, Vol.13 (1), p.99-110

2011

Volltextzugriff (PDF)

Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial

Cancer chemotherapy and pharmacology, 2020-11, Vol.86 (5), p.595-606

2020

Volltextzugriff (PDF)

Development of a first-in-class autologous B cell therapy for the treatment of Fabry disease

Molecular genetics and metabolism, 2024-02, Vol.141 (2), p.107818, Article 107818

2024

Volltextzugriff (PDF)

A Novel Allosteric Insulin Receptor-Activating Antibody Reduces Hyperglycemia without Hypoglycemia in Diabetic Cynomolgus Monkeys

The Journal of pharmacology and experimental therapeutics, 2016-02, Vol.356 (2), p.466

2016

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of CD4-Anchoring Bi-Functional Fusion Inhibitor in Monkeys

Pharmaceutical research, 2014-03, Vol.31 (3), p.809-818

2014

Volltextzugriff (PDF)

Automation Practices in Large Molecule Bioanalysis: Recommendations from Group L5 of the Global Bioanalytical Consortium

The AAPS journal, 2014-01, Vol.16 (1), p.164-171

2014

Volltextzugriff (PDF)

Cellular and Molecular Events Associated with the Bone-Protecting Activity of the Noncalcemic Vitamin D Analog Ro-26-9228 in Osteopenic Rats

Endocrinology (Philadelphia), 2002-05, Vol.143 (5), p.1625-1636

2002

Volltextzugriff (PDF)

Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats

Endocrinology (Philadelphia), 2002-05, Vol.143 (5), p.1625

2002

Volltextzugriff (PDF)

Effect of Cellular Environment on the Selective Activation of the Vitamin D Receptor by 1α,25-Dihydroxyvitamin D 3 and Its Analog 1α-Fluoro-16-Ene-20-Epi-23-Ene-26,27-Bishomo-25-Hydroxyvitamin D 3 (Ro-26-9228)

Molecular endocrinology (Baltimore, Md.), 2004-04, Vol.18 (4), p.874-887

2004

Volltextzugriff (PDF)

Effect of Cellular Environment on the Selective Activation of the Vitamin D Receptor by 1α,25-Dihydroxyvitamin D3 and Its Analog 1α-Fluoro-16-Ene-20-Epi-23-Ene-26,27-Bishomo-25-Hydroxyvitamin D3 (Ro-26-9228)

Molecular endocrinology (Baltimore, Md.), 2004-04, Vol.18 (4), p.874-887

2004

Volltextzugriff (PDF)

Effect of cellular environment on the selective activation of the vitamin D receptor by 1alpha,25-dihydroxyvitamin D3 and its analog 1alpha-fluoro-16-ene-20-epi-23-ene-26,27-bishomo-25-hydroxyvitamin D3 (Ro-26-9228)

Molecular endocrinology (Baltimore, Md.), 2004-04, Vol.18 (4), p.874-887

2004

Volltextzugriff (PDF)

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

mAbs, 2021, Vol.13 (1)

2021

Volltextzugriff (PDF)

Radioimmunochemical methods for the study of melanogenesis

Ahene, Ago B

1988

Volltextzugriff (PDF)

Melanin Standard Method: Empirical Formula 2

Pigment cell research, 1992-11, Vol.5 (5), p.240-246

1992

Volltextzugriff (PDF)

Analysis and Quantification of Pheomelanins by Radioimmunoassay

Pigment cell research, 1988-01, Vol.1 (5), p.326-331

1988

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(21)

Publikationsform

Sprache

Englisch
(23)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(12)
Animals
(10)
Pharmacology/toxicology
(8)
Biochemistry
(7)
Female
(7)
Pharmacology & Pharmacy
(7)
Biomedical And Life Sciences
(6)
Biomedicine
(6)
Male
(6)
Pharmacy
(6)
Biotechnology
(5)
Bemarituzumab
(4)
Ligands
(4)
Pharmacokinetics
(4)
Antibodies, Monoclonal - Pharmacokinetics
(3)
Chemistry
(3)
Medicine
(3)
Physical Sciences
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials

Magnetic bead extraction with acid dissociation immunoassay for the determination of serum CD80-Fc fusion protein

Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

Application and interpretation of free and total drug measurements in the development of biologics

Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats

Ligand Binding Assays in the 21st Century Laboratory—A Call for Change

Ligand Binding Assays in the 21st Century Laboratory: Automation

Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development

Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial

Development of a first-in-class autologous B cell therapy for the treatment of Fabry disease

A Novel Allosteric Insulin Receptor-Activating Antibody Reduces Hyperglycemia without Hypoglycemia in Diabetic Cynomolgus Monkeys

Pharmacokinetics and Pharmacodynamics of CD4-Anchoring Bi-Functional Fusion Inhibitor in Monkeys

Automation Practices in Large Molecule Bioanalysis: Recommendations from Group L5 of the Global Bioanalytical Consortium

Cellular and Molecular Events Associated with the Bone-Protecting Activity of the Noncalcemic Vitamin D Analog Ro-26-9228 in Osteopenic Rats

Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats

Effect of Cellular Environment on the Selective Activation of the Vitamin D Receptor by 1α,25-Dihydroxyvitamin D 3 and Its Analog 1α-Fluoro-16-Ene-20-Epi-23-Ene-26,27-Bishomo-25-Hydroxyvitamin D 3 (Ro-26-9228)

Effect of Cellular Environment on the Selective Activation of the Vitamin D Receptor by 1α,25-Dihydroxyvitamin D3 and Its Analog 1α-Fluoro-16-Ene-20-Epi-23-Ene-26,27-Bishomo-25-Hydroxyvitamin D3 (Ro-26-9228)

Effect of cellular environment on the selective activation of the vitamin D receptor by 1alpha,25-dihydroxyvitamin D3 and its analog 1alpha-fluoro-16-ene-20-epi-23-ene-26,27-bishomo-25-hydroxyvitamin D3 (Ro-26-9228)

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

Radioimmunochemical methods for the study of melanogenesis

Melanin Standard Method: Empirical Formula 2

Analysis and Quantification of Pheomelanins by Radioimmunoassay

Suchergebnisse filtern